ReviewF1000Research2017
Recent Advances in Endometrial Cancer.
Review in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The association between statin use and endometrial cancer survival outcome: A meta-analysis.Medicine · 2018Pooled it
- Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Mitochondrial Injury Accompanied by Intermediate Filament Remodeling Following Lithium Chloride Exposure in 3D Endometrial Cancer Spheroids.Biomedicines · 2026Article
- From guidelines to clinical practice: the impact of sentinel lymph node mapping on surgical management in endometrial cancer.Journal of medicine and life · 2025Article
- Genetically Proxied Therapeutic Effect of Lipid-Lowering Drugs Use, Breast Cancer, and Endometrial Cancer's Risk: A Drug Target-Based Mendelian Randomization Study.International journal of women's health · 2024Article
- lncRNA XIST/miR‑129‑2‑3p axis targets CCP110 to regulate the proliferation, invasion and migration of endometrial cancer cells.Experimental and therapeutic medicine · 2023Article
- CircSMAD2 accelerates endometrial cancer cell proliferation and metastasis by regulating the miR-1277-5p/MFGE8 axis.Journal of gynecologic oncology · 2023Article
- Article
- GLP1R inhibits the progression of endometrial carcinoma through activation of cAMP/PKA pathway.Journal of clinical laboratory analysis · 2022Article
- Sentinel lymph node mapping in endometrial cancer to reduce surgical morbidity: always, sometimes, or never.Przeglad menopauzalny = Menopause review · 2022Review
- Interferon‑stimulated gene 15 promotes progression of endometrial carcinoma and weakens antitumor immune response.Oncology reports · 2022Article
- Effect of metformin on proliferative markers in women with endometrial carcinoma: Systematic review and meta-analysis.Turkish journal of obstetrics and gynecology · 2022Article
- CircZNF124 regulates cell proliferation, leucine uptake, migration and invasion by miR-199b-5p/SLC7A5 pathway in endometrial cancer.Immunity, inflammation and disease · 2021Article
- Gynaecological cancers and their cell lines.Journal of cellular and molecular medicine · 2021Review
- CUL4A regulates endometrial cancer cell proliferation, invasion and migration by interacting with CSN6.Molecular medicine reports · 2021Article
- miR-27a acts as an oncogene to regulate endometrial cancer progression by targeting USP46.International journal of clinical and experimental pathology · 2021Article
- A clear cancer cell line (150057) derived from human endometrial carcinoma harbors two novel mutations.BMC cancer · 2020Article
- CircRNA hsa_circ_0002577 accelerates endometrial cancer progression through activating IGF1R/PI3K/Akt pathway.Journal of experimental & clinical cancer research : CR · 2020Article
- Bmi-1 Immunohistochemical Expression in Endometrial Carcinoma is Correlated with Prognostic Activity.Medicina (Kaunas, Lithuania) · 2020Article
- Endometrial cancer and its cell lines.Molecular biology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer is the most common gynecologic malignancy in the United States, with yearly rates continuing to increase. Most women present with early stage disease; however, advanced disease carries a grave prognosis. As a result, novel therapies are currently under investigation for the treatment of endometrial cancer. These advances include a better understanding of the genetic basis surrounding the development of endometrial cancer, novel surgical therapies, and new molecular targets for the treatment of this disease. This review explores the literature regarding these advancements in endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.